ArticleEMBO reports2005
Phosphorothioate-stimulated uptake of short interfering RNA by human cells.
Article in EMBO reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 58 citations in OpenAlex.
- Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.Pharmaceutics · 2022Review
- Melittin-Based Nano-Delivery Systems for Cancer Therapy.Biomolecules · 2022Review
- Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene SilencingNucleic acid therapeutics · 2021Article
- An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves siRNA stability.Scientific reports · 2020Article
- RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- Functional peptides for siRNA delivery.Advanced drug delivery reviews · 2017Review
- A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.Biotechnology advances · 2015Review
- Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.Molecules (Basel, Switzerland) · 2015Review
- Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.Nucleic acid therapeutics · 2014Review
- High-density lipoproteins for the systemic delivery of short interfering RNA.Expert opinion on drug delivery · 2014Review
- Automated solid-phase synthesis of RNA oligonucleotides containing a nonbridging phosphorodithioate linkage via phosphorothioamidites.The Journal of organic chemistry · 2012Article
- Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers.Journal of biological engineering · 2012Article
- Therapeutic siRNA: principles, challenges, and strategies.The Yale journal of biology and medicine · 2012Review
- Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.Bioconjugate chemistry · 2012Review
- Research progress on siRNA delivery with nonviral carriers.International journal of nanomedicine · 2011Review
- Engineering RNA for targeted siRNA delivery and medical application.Advanced drug delivery reviews · 2010Review
- DNA-based MRI probes for specific detection of chronic exposure to amphetamine in living brains.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009Article
- Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.RNA (New York, N.Y.) · 2009Article
- RNA interference: from basic research to therapeutic applications.Angewandte Chemie (International ed. in English) · 2009Review
- Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.Nucleic acids research · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cellular delivery of short interfering RNA (siRNA) is a main hurdle in therapeutic drug development. Here, we describe that phosphorothioate (PTO)-derived oligonucleotides stimulate the physical cellular uptake of siRNA in trans in human cells. This is reflected by an apparent dose-dependent siRNA-mediated suppression of lamin A/C in primary human umbilical vein endothelial cells. The PTO-stimulated cellular uptake in trans is concentration dependent, length dependent, related to the phosphorothioate chemistry but not sequence specific. We provide experimental evidence to support a caveolin-mediated uptake mechanism. In sum, this work strongly suggests the exploration of PTOs as facilitators in the delivery of biologically active siRNA to mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.